Latest research on Sevelamer

Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. When taken with meals, sevelamer binds to dietary phosphate and prevents its absorption. It is marketed by Genzyme under the trade name Renagel.

Sevelamer indications

Calcium-free binders (Sevelamer hydrochloride, Sevelamer carbonate, lanthanum carbonate) are equally or slightly less effective than calcium-based binders and their use does not seem to be associated with high calcium levels: this would reduce the risk for vascular calcifications. [source, 2016]
Bixalomer seems to effectively reduce phosphatemia with fewer gastrointestinal symptoms compared to Sevelamer hydrochloride. [source, 2016]
An example is Genz-644470, a polymer showing the ability to effectively reduce serum phosphate in hemodialysis patients but with no advantages over Sevelamer carbonate.44 [source, 2016]
The side effects more often observed in the sucroferric oxyhydroxide group were mild and transient diarrhea, discolored feces, and hyperphosphatemia; patients treated with Sevelamer mainly experienced constipation and nausea. [source, 2016]
This study concluded that sucroferric oxyhydroxide lowered serum phosphate in dialysis patients as effectively as Sevelamer carbonate but with a lower pill burden and better adherence to therapy. [source, 2016]
Although comparative clinical studies with lanthanum carbonate are lacking,43 sucroferric oxyhydroxide has proven to be as effective as Sevelamer with a similar rate of undesirable effects and the need for a lower number of pills. [source, 2016]
Moreover, sucroferric oxyhydroxide was able to reduce serum phosphate and intact Parathyroid hormone concentrations and prevent the development of vascular calcifications in a rat model of chronic renal failure as effectively as lanthanum carbonate and Sevelamer carbonate. [source, 2016]
Simultaneously, there has been an increase in utilization of non-calcium phosphate binders and several new resin-based products that have been approved by the Food and Drug Administration (FDA) for this indication, including Sevelamer hydrochloride, a non-absorbed synthetic polymer [6–9]. [source, 2016]
However, there is little information regarding gastrointestinal ulceration as a side effect; only a report of Sevelamer crystals isolated from the gastrointestinal tracts of patients with symptoms of gastrointestinal distress have been identified in the literature [15]. [source, 2016]
Treatment effect was achieved with approximately 62% fewer sucroferric oxyhydroxide tablets than Sevelamer tablets and was maintained over 24 weeks. [source, 2015]